Investorideas.com Newswire

Investorideas.com Newswire
Be one of the most talked about companies (stocks) on social media

Investorideas.com newswire, biotech stocks and industry

Monday, November 8, 2010

Biotech/Healthcare News: UV Flu Technologies, (UVFT.OB) Begins Shipments of Air Purifier to European Distributor

CENTERVILLE, MA � November 8, 2010 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) reports that shipments of its ViraTech UV-400 Air Purifier to its new European distributor Societe' Nema Citizen of Paris, France have commenced.
Societe' Nema Citizen (www.citizenfrance.com) is the largest distributor of Citizen Brand electronics in France, and also features a growing inventory of health and medical-related products available for distribution to retailers throughout much of Western Europe. The Company is well established and is providing an aggressive strategy designed to introduce the UV-400 to an existing consumer base utilizing extensive regional relationships and proven market penetration techniques.
"Early positive feedback supports our view that this order will be followed shortly with significant replenishment requests on an ongoing basis as we head into the winter cold and flu months," stated Jack Lennon, President of UV Flu Technologies. "Much of our initial shipment is slated for use as demonstration products specifically targeting fifty major catalog re-sellers. The distributor further supports these introductory efforts by offering a strong internet presence combined with a sizeable and knowledgeable sales force spread across the continent."
"We believe the European marketplace offers exceptional opportunities for us," said Mr. Lennon. "Europe has had incredible problems with MRSA, and other HAI's, or Hospital Associated Infections, which are bacterial strains that have grown impervious to antibiotics. In Wales recently, an outbreak of Legionnaires Disease brought the problem of poor air quality back as front page news. This disease is still widespread around the world, but experts believe it is usually misdiagnosed as pneumonia. The ViraTech UV-400 kills many of these types of airborne contaminants thereby minimizing their ability to spread, so we believe we can easily help reverse the possibility of dramatic increases in some of the most common, yet potentially deadly situations," said Mr. Lennon.
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/

Request info:
http://www.investorideas.com/Resources/Newsletter.asp

No comments:

Post a Comment